PRLD

In the past six months (April 2026 - October 2026), Prelude Therapeutics' stock was impacted by several events. The company released its Q1 2026 earnings on May 5, 2026, reporting a significantly smaller net loss and bolstering its cash runway. An April 2026 equity offering and pre-funded warrants generated approximately $85.4 million in net proceeds, strengthening liquidity. Q2 2026 financial results and a corporate update were reported on August 11, 2026. On September 10, 2026, the company received FDA clearance of its Investigational New Drug (IND) application for PRT13722, with a Phase 1 study anticipated in Q4 2026. Prelude Therapeutics participated in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. Over the last six months, PRLD stock fell by 14.00%, but it has seen a 31.38% increase year-to-date and a 170.21% increase over the last year, with analyst ratings showing a consensus of 'Hold' and some 'Buy' ratings with increased price targets.